Evidence map›Paper›PMID 41126739›Full record

ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026

Light Metabolically Reprograms CD8

Asmita Banstola, Shilin Gao, Zhengkung Zhang, Yan Dong, Prabhat Upadhyay, Quanwei Zhang, Yongli Li, Zuan-Tao Lin, Zhilong Wang, Mei X Wu

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Review
  3. Light Metabolically Reprograms CD8Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026
    Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Asmita BanstolaWellman Center for Photomedicine, Massachusetts General Hospital, Department of Dermatology, Harvard Medical School, 50 Blossom Street, Boston, MA, 02114, USA.
Shilin GaoWellman Center for Photomedicine, Massachusetts General Hospital, Department of Dermatology, Harvard Medical School, 50 Blossom Street, Boston, MA, 02114, USA.
Zhengkung ZhangWellman Center for Photomedicine, Massachusetts General Hospital, Department of Dermatology, Harvard Medical School, 50 Blossom Street, Boston, MA, 02114, USA.
Yan DongWellman Center for Photomedicine, Massachusetts General Hospital, Department of Dermatology, Harvard Medical School, 50 Blossom Street, Boston, MA, 02114, USA.
Prabhat UpadhyayWellman Center for Photomedicine, Massachusetts General Hospital, Department of Dermatology, Harvard Medical School, 50 Blossom Street, Boston, MA, 02114, USA.
Quanwei ZhangWellman Center for Photomedicine, Massachusetts General Hospital, Department of Dermatology, Harvard Medical School, 50 Blossom Street, Boston, MA, 02114, USA.
Yongli LiWellman Center for Photomedicine, Massachusetts General Hospital, Department of Dermatology, Harvard Medical School, 50 Blossom Street, Boston, MA, 02114, USA.
Zuan-Tao LinWellman Center for Photomedicine, Massachusetts General Hospital, Department of Dermatology, Harvard Medical School, 50 Blossom Street, Boston, MA, 02114, USA.
Zhilong WangWellman Center for Photomedicine, Massachusetts General Hospital, Department of Dermatology, Harvard Medical School, 50 Blossom Street, Boston, MA, 02114, USA.
Mei X WuWellman Center for Photomedicine, Massachusetts General Hospital, Department of Dermatology, Harvard Medical School, 50 Blossom Street, Boston, MA, 02114, USA.ORCID https://orcid.org/0000-0001-5456-5283

Funding

Biomimetic nanoparticles to enhance the breadth of influenza vaccinesR01AI146588 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI WU, MEI X · 2020 to 2024
$1.5M
American Cancer Society 132998-MBG-18-208-01Defense/Air Force of Scientific Research, Military Medical Photonics Program FA9550-20-1-0063NIAID NIH HHS R01 AI146588NIH HHS AI146588
6 · The paper itself

Abstract

Immunotherapy remains ineffective in many solid tumors due to poor T-cell infiltration and a metabolically suppressive tumor microenvironment. A dual strategy combining low-level light (LLL) therapy with a nanoscale stimulator of interferon genes (STING) agonist formulation (nanoSTING@Mn) is presented to enhance immune activation and metabolic fitness for durable tumor immunity against T-cell lymphoma (EL4) model. NanoSTING@Mn, composed of ADU-S100 complexed with Mn

Indexed as

CD8-Positive T-LymphocytesMembrane ProteinsAnimalsImmunotherapyMiceMice, Inbred C57BLNeoplasm MetastasisSTING ProteinTumor MicroenvironmentMembrane ProteinsSting1 protein, mouseSTING ProteincGAS–STING pathwayphoto‐biomodulationresident memory T cellstumor microenvironment

Identifiers

PMID41126739
PMCPMC12767170

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.